Association of tenofovir disoproxil fumarate exposure with chronic kidney disease and osteoporotic fracture in US veterans with HIV

References

• CDC. CDC Fact Sheet: Trends in U.S. HIV Diagnoses, 2005-2014 [Internet]. Atlanta (GA): CDC. 2017 [cited 2017 July 1]. Available from: https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/hiv-data-trends-fact-sheet-508.pdf
   Google Scholar
• Meir-Shafrir K, Pollack S. Accelerated Aging in HIV Patients. Rambam Maimonides Med J. 2012;3(4):e0025.
   PubMedGoogle Scholar
• The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–299.
   PubMed Web of Science ®Google Scholar
• Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450–454.
   PubMed Web of Science ®Google Scholar
• Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120–1126.
   PubMed Web of Science ®Google Scholar
• Miners A, Phillips A, Kreif N, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV. 2014;1(1):e32–e40.
   PubMed Web of Science ®Google Scholar
• Ando M, Yanagisawa N. Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients. World J Nephrol. 2015;4(3):388–395.
   PubMedGoogle Scholar
• Campos P, Ortiz A, Soto K. HIV and kidney diseases: 35 years of history and consequences. Clin Kidney J. 2016;9(6):772–781.
   PubMed Web of Science ®Google Scholar
• Ahmad AN, Ahmad SN, Ahmad N. HIV infection and bone abnormalities. Open Orthop J. 2017;11:777–784.
   PubMedGoogle Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–2174.
   PubMed Web of Science ®Google Scholar
• Güerri-Fernández R, Villar-García J, Díez-Pérez A, et al. HIV infection, bone metabolism, and fractures. Arq Bras Endocrinol Metabol. 2014;58(5):478–483.
   PubMedGoogle Scholar
• Battalora L. a, Young B, Overton ET. Bones, fractures, antiretroviral therapy and HIV. Curr Infect Dis Rep. 2014;16(2):393.
   PubMed Web of Science ®Google Scholar
• Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773–780.
   PubMed Web of Science ®Google Scholar
• Boyle SM, Malat G, Harhay MN, et al. Association of tenofovir disoproxil fumarate with primary allograft survival in HIV-positive kidney transplant recipients. Transpl Infect Dis. 2017;19(4):e12727.
   Web of Science ®Google Scholar
• Cooper RD, Wiebe N, Smith N, et al. Systematic Review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496–505.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10):1273–1281.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20(4):743–746.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004;18(7):1074–1076.
   PubMed Web of Science ®Google Scholar
• Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24(10):1519–1527.
   PubMed Web of Science ®Google Scholar
• Campbell LJ, Ibrahim F, Fisher M, et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10(6):329–336.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 2007;21:1119–1127.
   PubMed Web of Science ®Google Scholar
• Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6(7):1700–1707.
   PubMed Web of Science ®Google Scholar
• Veterans Affairs HIV/AIDS. VA HIV Testing Information for Health Care Providers [Internet]. Washington (DC): USDVA. 2017 [cited 2017 July 1]. Available from: https://www.hiv.va.gov/pdf/GetChecked-FactSheet-Provider.pdf
   Google Scholar
• Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825–831.
   PubMed Web of Science ®Google Scholar
• Islam FM, Wu J, Jansson J, et al. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health. 2012;12:234.
   PubMed Web of Science ®Google Scholar
• Lapadula G, Bernasconi DP, Casari S, et al. Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment. PLoS One. 2016;11(9):e0162320.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667–1678.
   PubMed Web of Science ®Google Scholar
• Menezes AM, Torelly J, Real L, et al. Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLoS One. 2011;6(10):e26042.
   PubMed Web of Science ®Google Scholar
• Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867–875.
   PubMed Web of Science ®Google Scholar
• Scherzer R, Gandhi M, Estrella MM, et al. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS. 2014;28:1289–1295.
   PubMed Web of Science ®Google Scholar
• Morlat P, Vivot A, Vandenhende MA, et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 aquitaine cohort, France, 2004-2012. PLoS One. 2013;8(6):e66223.
   PubMed Web of Science ®Google Scholar
• Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42(2):283–290.
   PubMed Web of Science ®Google Scholar
• Cuzin L, Pugliese P, Allavena C, et al. Antiretroviral therapy as a risk factor for chronic kidney disease: results from traditional regression modeling and causal approach in a large observational study. PLoS One. 2017;12(12):e0187517.
   PubMed Web of Science ®Google Scholar
• Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26:1907–1915.
   PubMed Web of Science ®Google Scholar
• Borges ÁH, Hoy J, Florence E, et al. Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort. Clin Infect Dis. 2017;64(10):1413–1421.
   PubMed Web of Science ®Google Scholar
• Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6(2):e17217.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2005;40(11):1559–1585.
   PubMed Web of Science ®Google Scholar
• Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS. 2007;21(15):2101–2103.
   PubMed Web of Science ®Google Scholar
• Wyatt CM. Antiretroviral therapy and the kidney. Top Antivir Med. 2014;22(3):655–658.
   PubMedGoogle Scholar
• Juega-Mariño J, Bonjoch A, Pérez-Alvarez N, et al. Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals. Medicine. 2017;96(37):e7421.
   PubMed Web of Science ®Google Scholar
• Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38(10):1933–1953.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–145.
   PubMed Web of Science ®Google Scholar
• Lafleur J, Bress A, Crook J, et al. Renal and bone outcomes among HIV-infected patients exposed to EFV/TDF/FTC compared with other tenofovir disoproxil fumarate–containing antiretroviral regimens: findings from the veterans health administration (VHA). Open Forum Infect Dis. 2016;3(1):S599.
   Google Scholar
• Poizot-Martin I, Solas C, Allemand J, et al. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2013;62(4):375–380.
   PubMed Web of Science ®Google Scholar